切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2020, Vol. 08 ›› Issue (02) : 117 -120. doi: 10.3877/cma.j.issn.2095-655X.2020.02.011

所属专题: 文献

临床研究

Galectin-3蛋白在人膀胱移行细胞癌诊断中的应用价值
陈强1, 左丙杰2, 刘岩1, 苏雷1, 孙国华1,()   
  1. 1. 271400 山东宁阳县第一人民医院泌尿外科
    2. 271024 泰安市满庄镇卫生院心血管内科
  • 收稿日期:2019-09-09 出版日期:2020-05-26
  • 通信作者: 孙国华
  • 基金资助:
    泰安市科技发展计划(2018NS0234)

The value of Galectin-3 protein in the diagnosis of human bladder transitional cell carcinoma

Qiang Chen1, Bingjie Zuo2, Yan Liu1, Lei Su1, Guohua Sun1,()   

  1. 1. Department of Urology, the First People′s Hospital of Ningyang County, Ningyang 271400, China
    2. Department of Cardiovascular Medicine, Manzhuang Town Health Center, Manzhuang 271024, China
  • Received:2019-09-09 Published:2020-05-26
  • Corresponding author: Guohua Sun
  • About author:
    Corresponding author: Sun Guohua, Email:
引用本文:

陈强, 左丙杰, 刘岩, 苏雷, 孙国华. Galectin-3蛋白在人膀胱移行细胞癌诊断中的应用价值[J]. 中华诊断学电子杂志, 2020, 08(02): 117-120.

Qiang Chen, Bingjie Zuo, Yan Liu, Lei Su, Guohua Sun. The value of Galectin-3 protein in the diagnosis of human bladder transitional cell carcinoma[J]. Chinese Journal of Diagnostics(Electronic Edition), 2020, 08(02): 117-120.

目的

探讨Galectin-3蛋白在人膀胱移行细胞癌诊断中的应用价值。

方法

收集2015年1月至2018年1月就诊于山东宁阳县第一人民医院泌尿外科接受经尿道电切术治疗的膀胱移行细胞癌患者84例,所有患者符合世界卫生组织中泌尿系统肿瘤病理学和诊断学的标准。采用免疫组织化学法检测Galectin-3蛋白的表达阳性率,比较分析Galectin-3蛋白在膀胱移行细胞癌组织中表达阳性率,及在不同病理分级、临床分期、初发以及复发肿瘤中表达阳性率的差异。

结果

Galectin-3蛋白在膀胱移行细胞癌组织的表达阳性率(66.67%,56/84)明显高于癌旁组织的表达阳性率(7.69%,4/52)(χ2=17.65,P<0.01);病理分级为G2(68.75%,22/32)和G3级(94.12%,16/17)的低分化膀胱移行细胞癌的Galectin-3蛋白表达阳性率明显高于病理分级为G1级(42.86%,15/35)的高分化膀胱移行细胞癌组织的表达(χ2=2.39,P<0.05);Galectin-3蛋白的表达阳性率随着临床分期的增高而增高,在临床分期为T3期时高达100.00%(12/12)(χ2=10.44,P<0.01);Galectin-3蛋白在复发膀胱移行细胞癌组织的表达阳性率(69.23%,18/26)高于初发膀胱移行细胞癌组织(62.07%,36/58),两组比较差异无统计学意义(χ2=0.35,P>0.05)。

结论

Galectin-3可作为诊断膀胱移行细胞癌和评估严重程度的生物标志物。

Objective

To investigate the value of Galectin-3 in the diagnosis of human bladder transitional cell carcinoma (TCC).

Methods

Galectin-3 was detected by immunohistochemistry in bladder TCC patients (n=84) who underwent transurethral resection from urology department, the First People′s Hospital of Ningyang County from January 2015 to January 2018. To analyze and compare the expression of Galectin-3 in bladder TCC and its role in pathological grading, clinical staging, initial occurrence and recurrence.

Results

The positive expression rate of Galectin-3 protein in bladder TCC was 66.67%(56/84), which was significantly higher than that in adjacent tissues (7.69%, 4/52) (χ2=17.65, P<0.01). The expression rates of Galectin-3 protein in poorly differentiated TCC of bladder (grade G2: 68.75%, 22/32, grade G3: 94.12%, 16/17) were significantly higher than that in well differentiated TCC of bladder (grade G1: 42.86%, 15/35) (χ2=2.39, P<0.05). The positive expression rate of Galectin-3 protein increased with the increase of clinical stage and reached 100%(12/12) (χ2=10.44, P<0.01) when the clinical stage was T3. The expression of Galectin-3 protein in recurrent bladder TCC (69.23%, 18/26) was higher than that in primary bladder TCC, but there was no significant difference (62.07%, 36/58) (χ2=0.35, P>0.05).

Conclusion

Galectin-3 can be used as a biomarker for the diagnosis and severity assessment of bladder TCC.

表1 Galectin-3 蛋白在人膀胱移行细胞癌患者不同病理分级表达阳性率的比较
表2 Galectin-3 蛋白与人膀胱移行细胞癌患者不同临床分期表达阳性率的比较
表3 Galectin-3 蛋白在人膀胱移行细胞癌初发与复发患者中表达阳性率的比较
[1]
Khorramdelazad H, Bagheri V, Hassanshahi G,et al.S100A12 and RAGE expression in human bladder transitional cell carcinoma: a role for the ligand/RAGE axis in tumor progression?[J].Asian Pac J Cancer Prev,2015,16(7):2725-2729.
[2]
Mc Carthy N. Bladder cancer: seemingly similar[J]. Nat Rev Cancer,2014,14(4):214-215.
[3]
Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis[J].Proc Natl Acad Sci U S A,1996,93(13):6737-6742.
[4]
Yoshii T, Fukumori T, Honjo Y,et al.Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest[J].J Biol Chem,2002,277(9):6852-6857.
[5]
Bresalier RS, Yan PS, Byrd JC,et al.Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system[J].Cancer,1997,80(4):776-787.
[6]
Konstantinov KN, Robbins BA, Liu FT.Galectin-3,a beta-galactoside-binding animal lectin,is a marker of anaplastic large-cell lymphoma[J].Am J Pathol,1996,148(1):25-30.
[7]
赵明,何向蕾,张大宏,等.WHO(2016)泌尿男性生殖系统肿瘤组织学分类解读[J].临床与实验病理学杂志,2017,33(2):119-124.
[8]
程亮,赵明.重新评价非浸润性乳头状尿路上皮肿瘤的组织学分级[J].中华病理学杂志,2014,43(12):848-852.
[9]
Kageshita T, Kashio Y, Yamauchi A,et al.Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance[J].Int J Cancer,2002,99(6):809-816.
[10]
Perillo NL, Pace KE, Seilhamer JJ,et al.Apoptosis of T cells mediated by galectin-1[J].Nature,1995,378(6558):736-739.
[11]
Liu FT, Patterson RJ, Wang JL.Intracellular functions of galectins[J].Biochim Biophys Acta,2002,1572(2/3):263-273.
[12]
苏赓,梁科庆,罗显克,等.结肠腺癌中MGMT和galectin-3的表达及其与淋巴结转移的关系[J].医学研究杂志,2019,48(4):63-66.
[13]
Yang RY, Liu FT.Galectins in cell growth and apoptosis[J].Cell Mol Life Sci,2003,60(2):267-276.
[14]
Barondes SH, Cooper DN, Gitt MA,et al.Galectins.Structure and function of a large family of animal lectins[J].J Biol Chem,1994,269(33):20807-20810.
[15]
Rabinovich, GA.Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy[J].Cell Death Differ,1999,6(8):711-721.
[16]
Takenaka Y, Inohara H, Yoshii T,et al.Malignant transformation of thyroid follicular cells by galectin-3[J].Cancer Lett,2003,195(1):111-119.
[17]
Yoshii T, Inohara H, Takenaka Y,et al.Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells[J].Int J Oncol,2001,18(4):787-792.
[18]
张瑞瑞,周武碧,潘振国,等.RNA干扰Rac1基因表达抑制胃癌细胞增殖及促进凋亡的机制研究[J].临床和实验医学杂志,2017,16(13):1279-1282.
[19]
Miyazaki J, Hokari R, Kato S,et al.Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes[J].Oncol Rep,2002,9(6):1307-1312.
[20]
Vereecken P, Zouaoui Boudjeltia K, Debray C, et al. High serum galectin-3 in advanced melanoma:preliminary results[J].Clin Exp Dermatol,2006,31(1):105-109.
[21]
李士坤,黄永斌.多器官尿路上皮癌误诊分析并文献复习[J/CD].中华诊断学电子杂志,2014,2(1):61-64.
[22]
Matarrese P, Fusco O, Tinari N,et al.Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties[J].Int J Cancer,2000,85(4):545-554.
[23]
Inohara H, Akahani S, Koths K,et al.Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion[J].Cancer Res,1996,56(19):4530-4534.
[24]
Kim HR, Lin HM, Biliran H,et al.Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells[J].Cancer Res,1999,59(16):4148-4154.
[25]
Yoshii T, Fukumori T, Honjo Y,et al.Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest[J].J Biol Chem,2002,277(9):6852-6857.
[1] 刘艳艳, 谭曦, 彭雪. 妊娠合并膀胱低度恶性潜能乳头状尿路上皮肿瘤并文献复习[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(02): 212-218.
[2] 左解鹏, 周典晟, 王健, 刘文博, 吴长利, 田大伟. 局麻下利用软性膀胱镜联合铥激光治疗麻醉高风险膀胱肿瘤患者的经验[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 563-569.
[3] 康海, 谭武宾, 周松, 毛正, 米泽振, 李铁求. 膀胱癌根治术后阴茎转移一例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 523-525.
[4] 罗辉, 熊珍珍, 黄令杰, 林山, 李金雨. 盆腔淋巴结大小对膀胱癌复发的影响[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 495-499.
[5] 刘恒, 侯宇川. 膀胱癌新型灌注药物的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 445-451.
[6] 梁耿祺, 关礼贤, 廖俊发, 徐勋. 1 470 nm激光膀胱肿瘤整块切除与传统电切治疗非肌层浸润性膀胱癌的比较[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 257-260.
[7] 董文. 肌层浸润性膀胱癌新辅助与辅助免疫治疗的现状与展望[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(01): 1-6.
[8] 薛胜, 李庆文, 刘建民, 汪盛, 王成勇, 刘贝贝, 李文永, 张晓乐, 代昌远. 腹腔镜保留前列腺尖部包膜根治性膀胱切除W形回肠新膀胱术尿控和勃起功能研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(01): 16-21.
[9] 郝超, 黄骥, 吴高亮, 郭维炜, 涂新华. 机器人辅助腹腔镜体内原位U形回肠新膀胱术的临床疗效观察及尿动力分析[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(01): 11-15.
[10] 江东, 周益红, 麦蕾, 吴振杰, 冼建忠, 戴英波. 二次电切在降低非肌层浸润性膀胱癌初次电切术后复发率中的临床价值[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(06): 513-517.
[11] 吴曦, 宋文, 高风雷, 董文奎, 黄恒, 黄兴. 膀胱副神经节瘤二例报告及文献复习[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(06): 555-558.
[12] 杨恒, 张家伟, 苏容万, 邓天星. 分腿俯卧位完成女性膀胱前壁肿瘤电切术十例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(05): 454-455.
[13] 郑琪, 杨帅, 王艳波, 侯宇川. 原发性膀胱绒毛状腺瘤合并腺癌一例报道[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(01): 91-92.
[14] 张敏, 费晓炜, 罗耀文, 付奕豪, 张磊, 高大宽. D-阿洛糖对OGD/R诱导的HT22细胞损伤及Gal-3表达的影响[J]. 中华神经创伤外科电子杂志, 2023, 09(03): 135-141.
[15] 闫忠孝. 经尿道钬激光膀胱肿瘤切除术与等离子膀胱肿瘤切除术治疗老年前列腺增生的疗效比较[J]. 中华老年病研究电子杂志, 2022, 09(03): 42-45.
阅读次数
全文


摘要